You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Les traitements par chimiothérapie et autres traitements systémiques pourraient être modifiés en raison de la COVID-19. Vous trouverez de plus amples renseignements à la page Traitements systémiques pendant la pandémie de la COVID-19.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

39 Items
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
Drugs Used:
bendamustine (PDRP prior authorization),
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Chronic Lymphocytic Leukemia
Apr 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Drugs Used:
bendamustine (Unfunded)
Jun 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade     
Intent: Palliative
Drugs Used:
riTUXimab (Unfunded),
polatuzumab vedotin (Unfunded),
bendamustine (Unfunded)
Feb 2020
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
Feb 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
riTUXimab (Unfunded),
bendamustine (Unfunded)
Oct 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
Dec 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
Jul 2018
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Exceptional Access Program
    vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019